Shirin Barez, MD
Ophthalmology · Hayward
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 4 carriers
- Offices
- 2
- Since medical school
- 38 years
- George Washington University School of Medicine, 1988
Offices
2 locations · Optima Ophthalmic Medical Associates Inc · Regents of the University of California at Berkeley
Looking this up.
Plans that list them
25 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barez’s office at (510) 886-5497 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G75048 · Current
Licensed to practise in California · since 1992 · expires 2028-08-31 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Original Medicare doctor bills
$922,372
Medicare paid this office $922,372 for 692 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 72 | $384,451 | None |
| Established patient problem focused exam of visual system | 392 | $89,259 | $85 |
| Injection, faricimab-svoa, 0.1 mg | 13 | $82,933 | None |
| Injection of drug into eye | 131 | $61,260 | $109 |
| Imaging of retina | 491 | $49,994 | $39 |
See all 20 services
| Injection, aflibercept, 1 mg | 72 | $384,451 | None |
| Established patient problem focused exam of visual system | 392 | $89,259 | $85 |
| Injection, faricimab-svoa, 0.1 mg | 13 | $82,933 | None |
| Injection of drug into eye | 131 | $61,260 | $109 |
| Imaging of retina | 491 | $49,994 | $39 |
| Established patient complete exam of visual system | 414 | $46,771 | $110 |
| Exam of visual field with extended testing | 190 | $15,163 | $61 |
| New patient visit (45+ min) | 101 | $12,761 | $126 |
| Short return visit (20+ min) | 81 | $9,263 | $81 |
| Compounded drug, not otherwise classified | 53 | $9,146 | None |
| Return visit (30+ min) | 76 | $8,295 | $99 |
| Removal of recurring cataract in lens capsule using a laser | 22 | $8,199 | $304 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 13 | $5,103 | $232 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 30 | $4,874 | $162 |
| Imaging of optic nerve | 90 | $3,010 | $33 |
| Photography of the retina | 46 | $1,572 | $34 |
| Extended exam of the back part of the eye with optic nerve drawing | 79 | $1,198 | $14 |
| Exam of the internal drainage system of eye | 38 | $1,093 | $27 |
| Short return visit | 19 | $991 | $52 |
| Ultrasound scan of cornea to determine thickness | 27 | $258 | $10 |
Procedures Medicare counted
| Cataract surgery | 29 | More than 52% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 788 | 653 | 744 | 853 | 664 | 561 |
| Destruction of leaking blood vessels of retina using laser | 65 | 57 | 70 | 45 | 16 | – |
| Removal of recurring cataract in lens capsule using a laser | – | – | 21 | 18 | – | 27 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | – | – | – | – | 18 | 22 |
| Removal of eyelashes using forceps | 17 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
692 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 20% · Women 59% · Also on Medicaid 53% · Health risk score 1.61. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 62% · Chronic kidney disease 38% · Coronary heart disease 26% · Heart failure 21% · Depression 15% · Cancer 13% · Atrial fibrillation 13% · Stroke 11% · COPD 10% · Dementia 7%.
The office billed $2,108,494, Medicare allowed $1,194,697 and paid $922,372; for 8,682 services of 42 kinds; $542,044 of it was for drugs given in the office and $380,327 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 692 | 8,682 | 76 | 1.61 | $2,108,494 | $922,372 |
| 2023 | 872 | 7,580 | 77 | 1.59 | $2,377,991 | $982,260 |
| 2022 | 902 | 7,496 | 77 | 1.47 | $2,867,202 | $1,240,297 |
| 2021 | 831 | 6,209 | 76 | 1.48 | $2,039,636 | $1,037,362 |
| 2020 | 609 | 5,246 | 76 | 1.69 | $1,450,528 | $718,103 |
| 2019 | 854 | 7,207 | 75 | 1.56 | $1,706,112 | $813,445 |
| 2018 | 862 | 7,668 | 75 | 1.62 | $1,665,709 | $791,010 |
| 2017 | 926 | 7,696 | 75 | 1.62 | $1,753,298 | $789,061 |
| 2016 | 919 | 7,719 | 75 | 1.52 | $2,009,717 | $937,454 |
| 2015 | 977 | 7,469 | 75 | 1.48 | $1,750,717 | $844,441 |
| 2014 | 1,039 | 6,672 | 75 | 1.52 | $1,485,988 | $703,472 |
| 2013 | 1,025 | 6,787 | 75 | 1.44 | $1,519,343 | $732,704 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Injection, aflibercept, 1 mg | 111 | $541,524 | None |
| Established patient problem focused exam of visual system | 446 | $83,085 | $83 |
| Injection of drug into eye | 173 | $71,515 | $108 |
| Established patient complete exam of visual system | 516 | $58,419 | $110 |
| Imaging of retina | 629 | $56,574 | $38 |
| Return visit (30+ min) | 138 | $17,383 | $95 |
| New patient visit (45+ min) | 100 | $13,859 | $139 |
| Short return visit (20+ min) | 91 | $13,681 | $83 |
| Exam of visual field with extended testing | 174 | $12,803 | $58 |
| Compounded drug, not otherwise classified | 59 | $9,606 | None |
| Photography of the retina | 166 | $9,566 | $33 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 12 | $4,256 | $236 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,255 | $266 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 27 | $3,936 | $146 |
| Imaging of optic nerve | 80 | $2,759 | $32 |
| Exam of the internal drainage system of eye | 32 | $732 | $23 |
| Ultrasound scan of cornea to determine thickness | 23 | $229 | $10 |
2022: 21 services
| Injection, aflibercept, 1 mg | 110 | $739,489 | None |
| Injection of drug into eye | 186 | $90,557 | $106 |
| Established patient problem focused exam of visual system | 410 | $81,131 | $82 |
| Imaging of retina | 666 | $66,522 | $38 |
| Established patient complete exam of visual system | 565 | $65,252 | $109 |
| Return visit (30+ min) | 203 | $37,418 | $109 |
| Injection, ranibizumab, 0.1 mg | 11 | $30,771 | None |
| Short return visit (20+ min) | 97 | $21,827 | $83 |
| Exam of visual field with extended testing | 206 | $16,594 | $58 |
| Photography of the retina | 229 | $13,189 | $34 |
| New patient visit (45+ min) | 94 | $12,721 | $135 |
| Destruction of leaking blood vessels of retina using laser | 18 | $11,889 | $264 |
| Compounded drug, not otherwise classified | 57 | $11,024 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 79 | $10,422 | $130 |
| Removal of recurring cataract in lens capsule using a laser | 17 | $5,452 | $303 |
| New patient visit (60+ min) | 20 | $2,857 | $143 |
| Imaging of optic nerve | 76 | $2,606 | $32 |
| Injection, bevacizumab, 10 mg | 13 | $2,347 | None |
| Short return visit | 37 | $2,066 | $50 |
| Exam of the internal drainage system of eye | 37 | $990 | $26 |
| Ultrasound scan of cornea to determine thickness | 39 | $407 | $10 |
2021: 19 services
| Injection, aflibercept, 1 mg | 97 | $565,228 | None |
| Injection of drug into eye | 178 | $80,746 | $109 |
| Established patient problem focused exam of visual system | 338 | $64,810 | $84 |
| Imaging of retina | 561 | $55,677 | $39 |
| Established patient complete exam of visual system | 484 | $55,315 | $111 |
| Return visit (30+ min) | 217 | $40,117 | $113 |
| Short return visit (20+ min) | 78 | $22,673 | $85 |
| Destruction of leaking blood vessels of retina using laser | 26 | $20,247 | $289 |
| Compounded drug, not otherwise classified | 82 | $14,992 | None |
| Exam of visual field with extended testing | 183 | $14,309 | $61 |
| New patient visit (45+ min) | 88 | $11,802 | $134 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 86 | $10,692 | $122 |
| Removal of recurring cataract in lens capsule using a laser | 21 | $6,476 | $308 |
| Photography of the retina | 136 | $5,358 | $37 |
| Imaging of optic nerve | 92 | $3,320 | $34 |
| Injection, bevacizumab, 10 mg | 18 | $2,940 | None |
| Short return visit | 19 | $1,155 | $55 |
| Exam of the internal drainage system of eye | 30 | $832 | $28 |
| Ultrasound scan of cornea to determine thickness | 39 | $413 | $11 |
2020: 19 services
| Injection, aflibercept, 1 mg | 56 | $352,279 | None |
| Established patient problem focused exam of visual system | 345 | $74,192 | $79 |
| Injection of drug into eye | 152 | $60,081 | $92 |
| Injection, ranibizumab, 0.1 mg | 18 | $46,402 | None |
| Imaging of retina | 441 | $46,328 | $38 |
| Established patient complete exam of visual system | 374 | $40,077 | $103 |
| Compounded drug, not otherwise classified | 83 | $16,387 | None |
| Destruction of leaking blood vessels of retina using laser | 19 | $15,939 | $280 |
| Short return visit (20+ min) | 50 | $11,020 | $66 |
| Exam of visual field with extended testing | 136 | $10,288 | $58 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 77 | $8,379 | $102 |
| New patient visit (45+ min) | 59 | $7,442 | $126 |
| Return visit (30+ min) | 46 | $6,235 | $88 |
| Photography of the retina | 95 | $3,967 | $39 |
| Injection, bevacizumab, 10 mg | 17 | $3,224 | None |
| Imaging of optic nerve | 60 | $1,895 | $30 |
| Extended exam of the back part of the eye with optic nerve drawing | 84 | $1,400 | $15 |
| Exam of the internal drainage system of eye | 18 | $455 | $25 |
| Ultrasound scan of cornea to determine thickness | 17 | $181 | $11 |
2019: 22 services
| Injection, aflibercept, 1 mg | 51 | $329,424 | None |
| Established patient problem focused exam of visual system | 477 | $100,544 | $79 |
| Injection of drug into eye | 191 | $71,855 | $91 |
| Imaging of retina | 527 | $54,311 | $38 |
| Injection, ranibizumab, 0.1 mg | 11 | $52,061 | None |
| Established patient complete exam of visual system | 479 | $50,293 | $102 |
| Compounded drug, not otherwise classified | 132 | $23,632 | None |
| Destruction of leaking blood vessels of retina using laser | 27 | $18,196 | $280 |
| Exam of visual field with extended testing | 178 | $14,905 | $58 |
| Short return visit (20+ min) | 71 | $14,551 | $64 |
| New patient visit (45+ min) | 114 | $13,812 | $121 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 142 | $13,667 | $89 |
| Examination of eye by ophthalmoscope with retinal drawing | 224 | $12,751 | $24 |
| Photography of the retina | 211 | $9,899 | $44 |
| Return visit (30+ min) | 42 | $5,148 | $94 |
| Examination of eye by ophthalmoscope with retinal drawing | 117 | $4,629 | $26 |
| Injection, bevacizumab, 10 mg | 19 | $4,281 | None |
| Imaging of optic nerve | 106 | $3,576 | $32 |
| 2d ultrasound scan of eye tissue and structures | 11 | $697 | $50 |
| Exam of the internal drainage system of eye | 24 | $685 | $26 |
| Removal of eyelashes using forceps | 12 | $561 | $33 |
| Ultrasound scan of cornea to determine thickness | 20 | $221 | $11 |
2018: 23 services
| Injection, aflibercept, 1 mg | 47 | $314,057 | None |
| Established patient problem focused exam of visual system | 486 | $96,529 | $77 |
| Injection of drug into eye | 174 | $64,140 | $91 |
| Injection, ranibizumab, 0.1 mg | 17 | $57,290 | None |
| Imaging of retina | 526 | $51,636 | $38 |
| Established patient complete exam of visual system | 429 | $47,153 | $101 |
| Compounded drug, not otherwise classified | 117 | $19,406 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 282 | $18,465 | $23 |
| Destruction of leaking blood vessels of retina using laser | 24 | $17,773 | $287 |
| Exam of visual field with extended testing | 207 | $16,331 | $58 |
| New patient visit (45+ min) | 115 | $13,991 | $122 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 137 | $12,328 | $82 |
| Photography of the retina | 212 | $11,100 | $49 |
| Short return visit (20+ min) | 70 | $8,173 | $62 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 18 | $6,106 | $218 |
| Examination of eye by ophthalmoscope with retinal drawing | 105 | $4,395 | $26 |
| Imaging of optic nerve | 119 | $4,271 | $34 |
| Injection, bevacizumab, 10 mg | 19 | $3,518 | None |
| Return visit (30+ min) | 19 | $1,944 | $85 |
| Exam of the internal drainage system of eye | 43 | $1,070 | $24 |
| Removal of eyelashes using forceps | 17 | $804 | $38 |
| Short return visit | 11 | $453 | $35 |
| Ultrasound scan of cornea to determine thickness | 23 | $315 | $14 |
2017: 24 services
| Injection, aflibercept, 1 mg | 44 | $310,934 | None |
| Injection, ranibizumab, 0.1 mg | 18 | $79,727 | None |
| Established patient problem focused exam of visual system | 486 | $76,987 | $72 |
| Established patient complete exam of visual system | 527 | $56,545 | $99 |
| Injection of drug into eye | 169 | $52,155 | $86 |
| Imaging of retina | 554 | $44,949 | $36 |
| Examination of eye by ophthalmoscope with retinal drawing | 377 | $26,110 | $22 |
| Destruction of leaking blood vessels of retina using laser | 28 | $18,361 | $266 |
| Exam of visual field with extended testing | 219 | $16,034 | $55 |
| Photography of the retina | 239 | $15,663 | $60 |
| Compounded drug, not otherwise classified | 101 | $14,425 | None |
| New patient visit (45+ min) | 99 | $12,565 | $127 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 155 | $11,941 | $71 |
| Short return visit (20+ min) | 75 | $9,940 | $59 |
| Examination of eye by ophthalmoscope with retinal drawing | 134 | $5,138 | $24 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 14 | $4,982 | $199 |
| Imaging of optic nerve | 118 | $3,943 | $31 |
| Return visit (30+ min) | 39 | $3,196 | $74 |
| Injection, bevacizumab, 10 mg | 15 | $2,333 | None |
| Laser repair to improve eye fluid flow | 11 | $2,194 | $183 |
| Removal of eyelashes using forceps | 24 | $1,530 | $41 |
| Exam of the internal drainage system of eye | 51 | $1,180 | $23 |
| Short return visit | 28 | $1,081 | $37 |
| Ultrasound scan of cornea to determine thickness | 31 | $376 | $12 |
2016: 25 services
| Injection, aflibercept, 1 mg | 63 | $436,532 | None |
| Injection, ranibizumab, 0.1 mg | 24 | $81,021 | None |
| Established patient problem focused exam of visual system | 521 | $74,117 | $71 |
| Injection of drug into eye | 148 | $49,939 | $87 |
| Established patient complete exam of visual system | 439 | $44,885 | $92 |
| Imaging of retina | 502 | $42,770 | $38 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 171 | $33,013 | $93 |
| Destruction of leaking blood vessels of retina using laser | 30 | $24,711 | $263 |
| Examination of eye by ophthalmoscope with retinal drawing | 357 | $24,090 | $22 |
| Photography of the retina | 267 | $19,054 | $66 |
| New patient visit (45+ min) | 135 | $16,874 | $125 |
| Exam of visual field with extended testing | 216 | $15,067 | $55 |
| Destruction of growth of retina using a laser | 19 | $14,017 | $438 |
| Compounded drug, not otherwise classified | 70 | $10,288 | None |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 30 | $9,314 | $183 |
| Short return visit (20+ min) | 60 | $7,327 | $59 |
| Examination of eye by ophthalmoscope with retinal drawing | 128 | $4,856 | $23 |
| Imaging of optic nerve | 101 | $3,842 | $37 |
| Return visit (30+ min) | 39 | $3,037 | $76 |
| Short return visit | 28 | $1,153 | $35 |
| Exam of the internal drainage system of eye | 48 | $1,061 | $21 |
| Injection, bevacizumab, 10 mg | 11 | $894 | None |
| New patient visit (15+ min) | 16 | $874 | $55 |
| Removal of eyelashes using forceps | 14 | $710 | $39 |
| Ultrasound scan of cornea to determine thickness | 29 | $351 | $12 |
2015: 24 services
| Injection, aflibercept, 1 mg | 56 | $329,128 | None |
| Established patient problem focused exam of visual system | 487 | $72,260 | $72 |
| Injection, ranibizumab, 0.1 mg | 20 | $70,342 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 216 | $49,676 | $95 |
| Injection of drug into eye | 127 | $42,487 | $87 |
| Imaging of retina | 492 | $42,325 | $39 |
| Established patient complete exam of visual system | 343 | $35,579 | $98 |
| Destruction of leaking blood vessels of retina using laser | 29 | $34,786 | $828 |
| Photography of the retina | 317 | $25,062 | $68 |
| Return visit (30+ min) | 267 | $23,140 | $78 |
| Examination of eye by ophthalmoscope with retinal drawing | 309 | $20,504 | $22 |
| Exam of visual field with extended testing | 227 | $15,997 | $56 |
| New patient visit (45+ min) | 124 | $14,823 | $120 |
| Destruction of growth of retina using a laser | 19 | $12,538 | $448 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 24 | $8,487 | $207 |
| Examination of eye by ophthalmoscope with retinal drawing | 173 | $7,107 | $24 |
| Unclassified biologics | 59 | $6,790 | None |
| Short return visit (20+ min) | 55 | $5,126 | $57 |
| Imaging of optic nerve | 102 | $3,854 | $36 |
| Compounded Drug, Not Otherwise Classified | 25 | $2,014 | $54 |
| Exam of the internal drainage system of eye | 49 | $1,107 | $22 |
| Removal of eyelashes using forceps | 12 | $711 | $44 |
| Short return visit | 19 | $663 | $30 |
| Ultrasound scan of cornea to determine thickness | 40 | $497 | $12 |
2014: 26 services
| Injection, ranibizumab, 0.1 mg | 29 | $150,100 | None |
| Injection, aflibercept, 1 mg | 26 | $125,205 | None |
| Established patient problem focused exam of visual system | 534 | $60,523 | $64 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 190 | $46,087 | $96 |
| Return visit (30+ min) | 353 | $39,542 | $94 |
| Destruction of leaking blood vessels of retina using laser | 32 | $39,330 | $855 |
| Injection of drug into eye | 115 | $38,430 | $90 |
| Imaging of retina | 429 | $34,987 | $39 |
| Photography of the retina | 278 | $22,314 | $67 |
| Established patient complete exam of visual system | 201 | $19,718 | $98 |
| Destruction of growth of retina using a laser | 30 | $17,984 | $461 |
| Examination of eye by ophthalmoscope with retinal drawing | 281 | $17,398 | $22 |
| New patient visit (45+ min) | 141 | $16,973 | $120 |
| Exam of visual field with extended testing | 226 | $14,552 | $54 |
| Unclassified biologics | 64 | $9,917 | None |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 24 | $8,099 | $213 |
| Examination of eye by ophthalmoscope with retinal drawing | 160 | $6,479 | $24 |
| Short return visit (20+ min) | 56 | $5,118 | $56 |
| Aspiration of eye fluid, complex | 13 | $4,831 | $322 |
| Imaging of optic nerve | 118 | $4,490 | $37 |
| Injection, bevacizumab, 10 mg | 15 | $1,385 | None |
| Short return visit | 29 | $1,385 | $36 |
| Removal of eyelashes using forceps | 17 | $942 | $45 |
| Exam of the internal drainage system of eye | 41 | $934 | $23 |
| New patient visit (15+ min) | 13 | $727 | $56 |
| Ultrasound scan of cornea to determine thickness | 34 | $438 | $13 |
2013: 25 services
| Injection, ranibizumab, 0.1 mg | 54 | $187,500 | None |
| Injection, aflibercept, 1 mg | 23 | $98,157 | None |
| Established patient problem focused exam of visual system | 620 | $91,160 | $73 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 231 | $53,086 | $98 |
| Destruction of leaking blood vessels of retina using laser | 35 | $47,094 | $841 |
| Imaging of retina | 438 | $34,239 | $41 |
| Injection of drug into eye | 113 | $31,021 | $91 |
| Photography of the retina | 325 | $25,097 | $66 |
| Destruction of growth of retina using a laser | 33 | $22,175 | $453 |
| Examination of eye by ophthalmoscope with retinal drawing | 325 | $18,642 | $22 |
| Established patient complete exam of visual system | 173 | $16,458 | $95 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 37 | $14,267 | $216 |
| Exam of visual field with extended testing | 195 | $12,847 | $58 |
| Return visit (30+ min) | 132 | $9,413 | $70 |
| Aspiration of eye fluid, complex | 25 | $9,113 | $314 |
| New patient visit (30+ min) | 110 | $9,026 | $82 |
| Examination of eye by ophthalmoscope with retinal drawing | 187 | $7,406 | $24 |
| New patient visit (45+ min) | 53 | $6,245 | $118 |
| Unclassified biologics | 49 | $5,589 | None |
| Short return visit (20+ min) | 55 | $4,727 | $53 |
| Imaging of optic nerve | 104 | $4,127 | $39 |
| Exam of the internal drainage system of eye | 73 | $1,752 | $23 |
| Short return visit | 32 | $1,746 | $39 |
| Removal of eyelashes using forceps | 17 | $958 | $42 |
| Ultrasound scan of cornea to determine thickness | 29 | $370 | $13 |
Medicaid work
$240,535 in 2024
Medicaid paid $240,535 for 3,411 billed services this clinician did in 2024, up to 108 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 155 | $113,125 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 871 | $36,498 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 414 | $22,877 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 969 | $17,766 |
| New patient visit (45+ min) | 178 | $17,471 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 262 | $16,542 |
| Injection, bevacizumab, 10 mg | 145 | $7,380 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 305 | $5,982 |
| Return visit (30+ min) | 33 | $2,216 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 79 | $679 |
| 2024 | 3,411 | 10 | 108 | $240,535 |
| 2023 | 3,139 | 10 | 93 | $227,156 |
| 2022 | 2,675 | 9 | 77 | $199,526 |
| 2021 | 2,720 | 11 | 71 | $175,284 |
| 2020 | 2,171 | 9 | 73 | $85,034 |
| 2019 | 3,048 | 13 | 73 | $115,918 |
| 2018 | 3,319 | 13 | 77 | $116,590 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 161 | $119,572 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 714 | $27,289 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 443 | $22,295 |
| New patient visit (45+ min) | 206 | $18,048 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 993 | $16,209 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 269 | $13,149 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 213 | $3,625 |
| Return visit (30+ min) | 72 | $3,554 |
| Injection, bevacizumab, 10 mg | 56 | $3,344 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 12 | $71 |
2022
| Aflibercept injection | 158 | $102,870 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 470 | $26,057 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 568 | $24,375 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 223 | $14,503 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 842 | $14,186 |
| Return visit (30+ min) | 139 | $5,742 |
| New patient visit (45+ min) | 55 | $5,580 |
| Injection, bevacizumab, 10 mg | 57 | $3,585 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 163 | $2,628 |
2021
| Aflibercept injection | 114 | $60,240 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 464 | $27,127 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 560 | $22,208 |
| TREATMENT X10SV RETINOPATHY | 79 | $14,304 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 769 | $13,276 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 245 | $12,863 |
| Injection, bevacizumab, 10 mg | 202 | $10,429 |
| New patient visit (45+ min) | 67 | $7,019 |
| Return visit (30+ min) | 101 | $6,111 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 100 | $1,479 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 19 | $228 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 584 | $24,295 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 418 | $20,771 |
| Injection, bevacizumab, 10 mg | 236 | $14,256 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 193 | $11,057 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 653 | $10,448 |
| TREATMENT X10SV RETINOPATHY | 16 | $3,423 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 39 | $364 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 20 | $273 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 12 | $147 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 521 | $28,803 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 635 | $26,959 |
| Injection, bevacizumab, 10 mg | 351 | $23,261 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 206 | $10,684 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 594 | $9,570 |
| New patient visit (45+ min) | 41 | $4,255 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 262 | $3,073 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 195 | $2,601 |
| TREATMENT X10SV RETINOPATHY | 18 | $2,577 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 45 | $2,032 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial | 80 | $1,091 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 57 | $907 |
2018
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 681 | $29,837 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 479 | $20,358 |
| Injection, bevacizumab, 10 mg | 295 | $18,133 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 253 | $14,744 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 607 | $8,828 |
| TREATMENT X10SV RETINOPATHY | 57 | $6,668 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 404 | $4,083 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 94 | $4,020 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 199 | $3,682 |
| New patient visit (45+ min) | 51 | $3,589 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 84 | $1,825 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial | 73 | $749 |
Drugs they prescribed that Part D paid
$118,887
Pharmacies billed $118,887 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,413) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
856 generic and fewer than 11 brand-name prescriptions · $118,887 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 20 | $20,129 | $1,006 |
| Lumigan | 23 | $14,870 | $647 |
| Vyzulta | 20 | $12,654 | $633 |
| Azopt | 12 | $8,434 | $703 |
| Latanoprost | 467 | $5,304 | $11 |
See all 15 drugs
| Restasis | 20 | $20,129 | $1,006 |
| Lumigan | 23 | $14,870 | $647 |
| Vyzulta | 20 | $12,654 | $633 |
| Azopt | 12 | $8,434 | $703 |
| Latanoprost | 467 | $5,304 | $11 |
| Brinzolamide | 13 | $4,048 | $311 |
| Cyclosporine | 14 | $4,004 | $286 |
| Prednisolone Acetate | 71 | $2,747 | $39 |
| Brimonidine | 131 | $2,594 | $20 |
| Dorzolamide | 173 | $2,257 | $13 |
| Dorzolamide-Timolol | 186 | $2,164 | $12 |
| Timolol Maleate | 99 | $838 | $8 |
| Ketorolac Tromethamine | 42 | $510 | $12 |
| Moxifloxacin | 11 | $436 | $40 |
| Neomycin-Polymyxin-Dexameth | 17 | $196 | $12 |
Year by year
| 2024 | 1,413 | 288 | 0% (0) | None | $118,887 |
| 2023 | 1,241 | 264 | 0% (0) | 42% | $154,986 |
| 2022 | 1,387 | 273 | 0% (0) | 43% | $180,721 |
| 2021 | 1,390 | 313 | 0% (0) | 48% | $154,917 |
| 2020 | 1,284 | 256 | 0% (0) | 40% | $113,537 |
| 2019 | 1,570 | 271 | 0% (0) | 38% | $130,946 |
| 2018 | 1,780 | 300 | 0% (0) | 39% | $118,937 |
| 2017 | 1,783 | 300 | 0% (0) | 36% | $131,971 |
| 2016 | 1,834 | 323 | 0% (0) | 33% | $115,409 |
| 2015 | 2,103 | 340 | 0% (0) | None | $139,489 |
| 2014 | 2,349 | 412 | None | None | $153,256 |
| 2013 | 2,238 | 456 | 0% (0) | 50% | $147,584 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Restasis | 38 | $42,941 | $1,130 |
| Lumigan | 22 | $15,065 | $685 |
| Latanoprost | 444 | $11,406 | $26 |
| Vyzulta | 15 | $7,259 | $484 |
| Alphagan P | 13 | $7,107 | $547 |
| Dorzolamide-Timolol | 149 | $5,046 | $34 |
| Dorzolamide | 150 | $4,770 | $32 |
| Brimonidine | 104 | $3,205 | $31 |
| Travoprost | 11 | $2,407 | $219 |
| Prednisolone Acetate | 48 | $1,936 | $40 |
| Timolol Maleate | 68 | $1,402 | $21 |
| Ketorolac Tromethamine | 18 | $508 | $28 |
| Neomycin-Polymyxin-Dexameth | 18 | $267 | $15 |
2022: 18 drugs
| Restasis | 31 | $37,446 | $1,208 |
| Lumigan | 30 | $17,604 | $587 |
| Azopt | 16 | $12,785 | $799 |
| Latanoprost | 536 | $11,648 | $22 |
| Vyzulta | 21 | $10,186 | $485 |
| Rhopressa | 11 | $9,861 | $896 |
| Simbrinza | 18 | $8,025 | $446 |
| Dorzolamide-Timolol | 155 | $7,358 | $47 |
| Alphagan P | 11 | $6,338 | $576 |
| Prednisolone Acetate | 53 | $3,217 | $61 |
| Dorzolamide | 83 | $2,605 | $31 |
| Timolol Maleate | 106 | $1,904 | $18 |
| Brimonidine | 80 | $1,701 | $21 |
| Valacyclovir | 13 | $1,243 | $96 |
| Ketorolac Tromethamine | 29 | $775 | $27 |
| Azelastine | 14 | $644 | $46 |
| Neomycin-Polymyxin-Dexameth | 23 | $320 | $14 |
| Cromolyn | 15 | $215 | $14 |
2021: 21 drugs
| Restasis | 18 | $23,439 | $1,302 |
| Lumigan | 47 | $19,522 | $415 |
| Latanoprost | 499 | $13,400 | $27 |
| Rhopressa | 21 | $11,733 | $559 |
| Dorzolamide-Timolol | 166 | $8,681 | $52 |
| Azopt | 17 | $8,317 | $489 |
| Vyzulta | 11 | $6,559 | $596 |
| Travoprost | 11 | $5,839 | $531 |
| Durezol | 18 | $4,277 | $238 |
| Simbrinza | 16 | $4,254 | $266 |
| Dorzolamide | 88 | $3,346 | $38 |
| Prednisolone Acetate | 51 | $3,179 | $62 |
| Brimonidine | 72 | $2,438 | $34 |
| Azelastine | 33 | $1,474 | $45 |
| Timolol Maleate | 74 | $1,227 | $17 |
| Ketorolac Tromethamine | 42 | $1,209 | $29 |
| Olopatadine | 13 | $428 | $33 |
| Neomycin-Polymyxin-Dexameth | 29 | $392 | $14 |
| Ofloxacin | 14 | $250 | $18 |
| Cromolyn | 14 | $184 | $13 |
| Prednisone | 13 | $104 | $8 |
2020: 18 drugs
| Lumigan | 34 | $12,213 | $359 |
| Latanoprost | 526 | $11,744 | $22 |
| Travatan Z | 17 | $8,091 | $476 |
| Dorzolamide-Timolol | 131 | $7,823 | $60 |
| Azopt | 21 | $7,397 | $352 |
| Rhopressa | 16 | $7,276 | $455 |
| Durezol | 16 | $4,554 | $285 |
| Dorzolamide | 115 | $3,947 | $34 |
| Nevanac | 14 | $3,764 | $269 |
| Travoprost | 11 | $2,848 | $259 |
| Combigan | 12 | $2,525 | $210 |
| Brimonidine | 76 | $1,798 | $24 |
| Prednisolone Acetate | 27 | $1,749 | $65 |
| Ketorolac Tromethamine | 43 | $1,115 | $26 |
| Timolol Maleate | 64 | $857 | $13 |
| Cromolyn | 17 | $260 | $15 |
| Neomycin-Polymyxin-Dexameth | 15 | $228 | $15 |
| Ofloxacin | 12 | $141 | $12 |
2019: 18 drugs
| Lumigan | 69 | $21,518 | $312 |
| Travatan Z | 36 | $14,885 | $413 |
| Latanoprost | 592 | $11,922 | $20 |
| Azopt | 26 | $11,681 | $449 |
| Rhopressa | 31 | $9,653 | $311 |
| Dorzolamide-Timolol | 164 | $7,991 | $49 |
| Olopatadine | 69 | $5,102 | $74 |
| Simbrinza | 18 | $3,795 | $211 |
| Brimonidine | 130 | $3,609 | $28 |
| Dorzolamide | 126 | $3,568 | $28 |
| Pazeo | 15 | $3,292 | $219 |
| Durezol | 15 | $2,898 | $193 |
| Prednisolone Acetate | 34 | $1,474 | $43 |
| Timolol Maleate | 88 | $1,157 | $13 |
| Ketorolac Tromethamine | 31 | $676 | $22 |
| Neomycin-Polymyxin-Dexameth | 24 | $333 | $14 |
| Cromolyn | 17 | $197 | $12 |
| Ofloxacin | 12 | $185 | $15 |
2018: 19 drugs
| Lumigan | 91 | $27,623 | $304 |
| Travatan Z | 48 | $14,102 | $294 |
| Azopt | 36 | $12,303 | $342 |
| Latanoprost | 671 | $12,047 | $18 |
| Olopatadine | 55 | $5,233 | $95 |
| Brimonidine | 163 | $5,176 | $32 |
| Dorzolamide-Timolol | 153 | $4,237 | $28 |
| Alphagan P | 11 | $4,043 | $368 |
| Cosopt Pf | 11 | $3,298 | $300 |
| Timolol Maleate | 151 | $3,181 | $21 |
| Prednisolone Acetate | 49 | $2,745 | $56 |
| Simbrinza | 17 | $2,713 | $160 |
| Dorzolamide | 119 | $2,697 | $23 |
| Combigan | 12 | $1,930 | $161 |
| Ketorolac Tromethamine | 39 | $868 | $22 |
| Ofloxacin | 24 | $369 | $15 |
| Neomycin-Polymyxin-Dexameth | 19 | $269 | $14 |
| Cromolyn | 34 | $212 | $6 |
| Diclofenac | 14 | $175 | $13 |
2017: 19 drugs
| Lumigan | 139 | $38,802 | $279 |
| Travatan Z | 61 | $15,600 | $256 |
| Latanoprost | 590 | $9,969 | $17 |
| Azopt | 30 | $9,834 | $328 |
| Brimonidine | 172 | $8,132 | $47 |
| Alphagan P | 13 | $6,428 | $494 |
| Dorzolamide | 182 | $4,244 | $23 |
| Dorzolamide-Timolol | 156 | $3,931 | $25 |
| Timolol Maleate | 120 | $3,299 | $27 |
| Pataday | 18 | $3,039 | $169 |
| Simbrinza | 15 | $2,556 | $170 |
| Prednisolone Acetate | 40 | $2,214 | $55 |
| Olopatadine | 15 | $1,804 | $120 |
| Durezol | 11 | $1,764 | $160 |
| Atropine Sulfate | 14 | $733 | $52 |
| Ofloxacin | 34 | $496 | $15 |
| Cromolyn | 47 | $317 | $7 |
| Neomycin-Polymyxin-Dexameth | 13 | $221 | $17 |
| Flurbiprofen | 20 | $165 | $8 |
2016: 19 drugs
| Lumigan | 113 | $27,132 | $240 |
| Travatan Z | 62 | $16,147 | $260 |
| Azopt | 29 | $11,001 | $379 |
| Latanoprost | 690 | $9,881 | $14 |
| Restasis | 13 | $7,306 | $562 |
| Nevanac | 23 | $7,285 | $317 |
| Brimonidine | 140 | $6,525 | $47 |
| Dorzolamide-Timolol | 185 | $4,931 | $27 |
| Dorzolamide | 182 | $4,061 | $22 |
| Prednisolone Acetate | 63 | $3,672 | $58 |
| Pataday | 17 | $2,750 | $162 |
| Timolol Maleate | 88 | $2,695 | $31 |
| Combigan | 13 | $2,420 | $186 |
| Durezol | 12 | $1,843 | $154 |
| Neomycin-Polymyxin-Dexameth | 36 | $648 | $18 |
| Olopatadine | 11 | $615 | $56 |
| Ofloxacin | 25 | $455 | $18 |
| Cromolyn | 44 | $332 | $8 |
| Flurbiprofen | 25 | $236 | $9 |
2015: 18 drugs
| Lumigan | 148 | $32,321 | $218 |
| Travatan Z | 78 | $15,049 | $193 |
| Azopt | 39 | $14,645 | $376 |
| Nevanac | 50 | $11,591 | $232 |
| Brimonidine | 177 | $10,502 | $59 |
| Latanoprost | 757 | $9,575 | $13 |
| Combigan | 35 | $5,218 | $149 |
| Prednisolone Acetate | 58 | $4,916 | $85 |
| Dorzolamide-Timolol | 193 | $4,862 | $25 |
| Timolol Maleate | 116 | $4,136 | $36 |
| Dorzolamide | 181 | $4,132 | $23 |
| Patanol | 17 | $4,079 | $240 |
| Simbrinza | 22 | $2,813 | $128 |
| Pataday | 11 | $1,715 | $156 |
| Neomycin-Polymyxin-Dexameth | 47 | $747 | $16 |
| Cromolyn | 64 | $511 | $8 |
| Ciprofloxacin | 15 | $184 | $12 |
| Flurbiprofen | 15 | $144 | $10 |
2014: 21 drugs
| Lumigan | 187 | $33,196 | $178 |
| Travatan Z | 120 | $18,318 | $153 |
| Brimonidine | 212 | $17,393 | $82 |
| Azopt | 63 | $13,940 | $221 |
| Latanoprost | 597 | $10,194 | $17 |
| Nevanac | 56 | $9,803 | $175 |
| Prednisolone Acetate | 83 | $6,110 | $74 |
| Dorzolamide | 187 | $6,023 | $32 |
| Dorzolamide-Timolol | 185 | $5,854 | $32 |
| Alphagan P | 19 | $4,677 | $246 |
| Combigan | 32 | $4,576 | $143 |
| Pataday | 22 | $3,049 | $139 |
| Timolol Maleate | 101 | $2,668 | $26 |
| Lotemax | 13 | $1,790 | $138 |
| Simbrinza | 17 | $1,662 | $98 |
| Ciprofloxacin | 136 | $1,546 | $11 |
| Doxycycline Hyclate | 12 | $1,522 | $127 |
| Neomycin-Polymyxin-Dexameth | 73 | $1,375 | $19 |
| Cromolyn | 106 | $1,153 | $11 |
| Flurbiprofen | 25 | $322 | $13 |
| Erythromycin | 15 | $233 | $16 |
2013: 19 drugs
| Lumigan | 218 | $36,149 | $166 |
| Travatan Z | 162 | $23,548 | $145 |
| Azopt | 74 | $14,204 | $192 |
| Nevanac | 66 | $9,773 | $148 |
| Dorzolamide-Timolol | 179 | $7,380 | $41 |
| Brimonidine | 123 | $6,953 | $57 |
| Pataday | 52 | $6,580 | $127 |
| Latanoprost | 360 | $5,935 | $16 |
| Dorzolamide | 147 | $5,650 | $38 |
| Combigan | 34 | $5,191 | $153 |
| Alphagan P | 29 | $4,448 | $153 |
| Prednisolone Acetate | 109 | $2,969 | $27 |
| Patanol | 21 | $2,897 | $138 |
| Ciprofloxacin | 175 | $2,640 | $15 |
| Cromolyn | 140 | $2,424 | $17 |
| Timolol Maleate | 94 | $1,782 | $19 |
| Neomycin-Polymyxin-Dexameth | 101 | $1,765 | $17 |
| Flurbiprofen | 46 | $515 | $11 |
| Erythromycin | 15 | $238 | $16 |
Money from drug and device companies
$175 in 2025
| 2025 | 5 | 7 | None | $175 |
| 2024 | 8 | 13 | None | $662 |
| 2023 | 4 | 7 | None | $182 |
| 2022 | 6 | 10 | None | $208 |
| 2021 | 6 | 8 | None | $155 |
| 2020 | 3 | 5 | None | $100 |
| 2019 | 3 | 8 | None | $161 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Syfovre | $57 | 2 payments
|
| Genentech USA | Vabysmo | $43 | 2 payments
|
| Harrow Eye | Vevye | $34 | 1 payment
|
| Alcon Vision | Eysuvis | $26 | 1 payment
|
| Optos | Nfc-700 | $16 | 1 payment
|
See all 7 published payments
| Harrow Eye | Meals · 2025-11-13 | Vevye | $34 |
| Genentech USA | Meals · 2025-10-27 | Vabysmo | $24 |
| Apellis Pharmaceuticals | Meals · 2025-07-29 | Syfovre | $29 |
| Optos | Entertainment · 2025-07-22 | Nfc-700 | $16 |
| Alcon Vision | Meals · 2025-07-10 | Eysuvis | $26 |
| Genentech USA | Meals · 2025-06-10 | Vabysmo | $19 |
| Apellis Pharmaceuticals | Meals · 2025-03-25 | Syfovre | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $662
| Biotissue Holdings | None | $203 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $156 | 2 payments
|
| EyePoint Pharmaceuticals US | Eyp-1901 | $104 | 1 payment
|
| Genentech USA | Vabysmo | $102 | 4 payments
|
| Astellas Pharma US | Izervay | $30 | 1 payment
|
| Alcon Vision | Rocklatan | $24 | 1 payment
|
| RxSight | Rxsight Contact Lens | $24 | 1 payment
|
| Bausch & Lomb Americas | Miebo | $20 | 1 payment
|
2023: $182
| Genentech USA | Vabysmo | $83 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $43 | 2 payments
|
| Merz Pharmaceuticals | Xeomin | $34 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $21 | 1 payment
|
2022: $208
| Johnson & Johnson Surgical Vision | Tecnis Iol | $77 | 4 payments
|
| Alcon Vision | Simbrinza | $42 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $26 | 1 payment
|
| Genentech USA | Vabysmo | $24 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $23 | 1 payment
|
| Allergan | Vuity | $16 | 1 payment
|
2021: $155
| Allergan | Restasis Multidose | $61 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $21 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $21 | 1 payment
|
| Aerie Pharmaceuticals | Rocklatan | $21 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $17 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $14 | 1 payment
|
2020: $100
| Novartis Pharmaceuticals | Xiidra | $42 | 2 payments
|
| Allergan | Restasis | $34 | 2 payments
|
| CooperVision | Misight Contact Lens | $25 | 1 payment
|
2019: $161
| Novartis Pharmaceuticals | Beovu | $110 | 5 payments
|
| Allergan | Lumigan | $26 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $25 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 86.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1659338952
- Licence
- CA G75048California G75048: Current · expires 2028-08-31
- Trained
- George Washington University School of Medicine, 1988 · 38 years ago
- Group
- Optima Ophthalmic Medical Associates Inc · Regents of the University of California at Berkeley
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 22634 2nd St Ste 101, Hayward, CA, 94541
- NPI first listed
- 2006-04-28
- NPI last updated
- 2008-09-03
This is when the NPI record was last certified, not a medical board exam.